Investical Earnings & investing calendar Earnings & investing calendar
/
CCarna Biosciences,Inc. logo
4572TSE Growth

Carna Biosciences,Inc.

カルナバイオサイエンス Yahoo Finance

Recent & upcoming events

Aug 6
Earnings 2:00
Q2 earnings announcement (scheduled)
Add to Google Calendar
May 8
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Mar 25
Shareholder meeting 1:00
Shareholders' meeting
Venue: 神戸国際ビジネスセンター（KIBC）4階会議室 兵庫県神戸市中央区港島南町五丁目5番2号 Details
Add to Google Calendar
Feb 10
Earnings 1:00
FY earnings announcement (scheduled)
Add to Google Calendar
Nov 6
Earnings 1:00 approx.
Q3 earnings announcement (scheduled)
Add to Google Calendar
2027
Feb 5
Est.
Earnings 1:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
May 7
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
Aug 6
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
Oct 29
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar

KPI highlights

FY25
Revenue ¥579M YoY -9.0%
Operating income ¥-2.07B margin -358.3%
Net income ¥-2.17B YoY —
EPS ¥-114 YoY —
P/E —
ROE —

Company guidance

FY2026/12 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥720M +24.3%
Operating income ¥-2.03B —
Net income ¥-2.09B —
EPS ¥-109 —

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q1FY26 Q1
Revenue ¥211M¥915M¥181M¥135M——
Operating income ¥-338M¥85M¥-416M¥-679M——
Net income ¥-345M¥77M¥-399M¥-695M——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2020–2025）

海外機関 7%個人 11.8%未開示 78.6%202020212022202320242025
事業法人国内機関海外機関個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

MSIP CLIENT SECURI 5%MSIP CLIENT SECURITIES（常任代理人　モルガン・スタンレーMUFG証券株式会社）川村　剛 2.9%川村　剛小野薬品工業株式会社 2.6%小野薬品工業株式会社上原　俊彦 2.6%上原　俊彦堀田　和男 2.4%堀田　和男吉野　公一郎 1.7%吉野　公一郎小川　義水 1.3%小川　義水BNY GCM CLIENT ACC 1%BNY GCM CLIENT ACCOUNT JPRD AC ISG （FE－AC）（常任代理人　株式会社三菱UFJ銀行）鈴木　隆啓 0.8%鈴木　隆啓202020212022202320242025

Top shareholders — actual figures (as of 2025)

Holder Shares held Ratio Source
MSIP CLIENT SECURITIES 955,612 5.0% Yuho (EDINET)
川村 剛 555,500 2.9% Yuho (EDINET)
小野薬品工業株式会社 504,500 2.6% Yuho (EDINET)
上原 俊彦 500,000 2.6% Yuho (EDINET)
堀田 和男 468,800 2.4% Yuho (EDINET)
吉野 公一郎 333,900 1.7% Yuho (EDINET)
小川 義水 255,000 1.3% Yuho (EDINET)
BNY GCM CLIENT ACCOUNT JPRD AC ISG （FE－AC） 195,241 1.0% Yuho (EDINET)
BNYM SA／NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE 180,304 0.9% Yuho (EDINET)
鈴木 隆啓 149,000 0.8% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

2/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✗ Positive ROA ROA -176.6%
✗ Positive operating cash flow ¥-2.16B
✗ ROA improved YoY -78.6% → -176.6%
✓ Operating CF exceeds net income (accrual quality) OCF ¥-2.16B / net income ¥-2.17B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 89.3% → 25.1%
✗ Current ratio improved 12.28× → 6.99×
✗ No dilution (shares outstanding did not increase) 19,107,500 → 19,150,500
✗ Gross margin improved 73.2% → 67.0%
✓ Asset turnover improved 0.23× → 0.47×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio 25.1%
Current ratio 7.0×
Years of positive operating CF 1 of last 10 yrs
Payout ratio —
Latest fiscal year result Loss (net loss ¥2.17B)

Performance history

Last 10 years
0億円8億円16億円24億円32億円 FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Income & assets

Unit: ¥100M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue 8.126.587.5532.111.320.213.916.36.365.79
Operating income -4.24-6.99-11.49.78-10.6-5.31-12.7-11.2-20.8-20.7
Ordinary income -4.41-7.11-11.69.57-10.8-5.23-12.8-11.3-20.8-21.4
Net income -2.90-7.37-12.18.28-11.1-5.34-13.5-11.5-21.8-21.7
Total assets 25.721.917.753.848.454.342.743.527.712.3
Equity 17.413.88.8738.538.243.236.438.824.83.09

Indicators & cash flow

Unit: ¥100M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
EPS ¥-32¥-79¥-125¥76¥-90¥-42¥-99¥-69¥-122¥-114
ROE ———35.1%——————
Operating CF -4.53-5.61-11.314.8-12.6-15.4-7.08-16.8-13.7-21.6
Investing CF 2.48-0.38-0.58-0.41-0.70-0.42-1.26-0.11-0.13-0.25
Financing CF 7.552.966.8821.27.2410.63.6711.85.676.05
FCF -2.05-5.99-11.914.4-13.3-15.8-8.34-16.9-13.9-21.8

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector

IR disclosure history

Timely disclosures & annual reports
Is this information incorrect?

Data provided by Twelve Data